ライフサイエンスコーパス: vaginalis

1 partial draft genomes (including Trichomonas vaginalis).

2 tted infections (STIs) caused by Trichomonas vaginalis.

3 al samples tested, 6.6% were positive for T. vaginalis.

4 ification test (NAAT) were used to detect T. vaginalis.

5 extraurogenital sources, with a focus on T. vaginalis.

6 Women were also tested for Trichomonas vaginalis.

7 ernatants from growing liquid cultures of G. vaginalis.

8 ion to alpha-actinin suggests exposure to T. vaginalis.

9 nes, to genetically characterize Trichomonas vaginalis.

10 ic or symptomatic, should be screened for T. vaginalis.

11 ic diversity, and population structure of T. vaginalis.

12 extracellular protozoan parasite Trichomonas vaginalis.

13 mplification (TMA) assay for detection of T. vaginalis.

14 erall, 5.1% of subjects were positive for T. vaginalis.

15 trains, from 4 other clinical isolates of T. vaginalis.

16 ify a fibronectin (FN)-binding protein of T. vaginalis.

17 ed to screen a cDNA expression library of T. vaginalis.

18 virulence potential of the BV associated G. vaginalis.

19 ptostreptococcus anaerobius, and Gardnerella vaginalis.

20 actor in the protozoan parasite, Trichomonas vaginalis.

21 VCU-M1, which is also associated with T. vaginalis.

22 grouped into 3 subclasses, are present in T. vaginalis.

23 spp., Gardnerella vaginalis, and Trichomonas vaginalis.

24 prevalences were 1.3% for C. trachomatis/T. vaginalis, 0.61% for C. trachomatis/N. gonorrhoeae and N

25 C trachomatis, 6.1% (4.0%-8.3%; n = 357), T vaginalis, 17.8% (12.4%-23.1%; n = 822), bacterial vagin

26 C trachomatis, 6.9% (5.1%-8.6%; n = 350), T vaginalis, 29.1% (20.9%-37.2%; n = 5502), bacterial vagi

27 The mean age of women with detectable T. vaginalis (30.6) was significantly higher than those for

28 I phenotype reflected detection of solely T. vaginalis (54.2% of all health care encounters that resu

29 te from other facilities exceeded that of T. vaginalis (7.2%; P = 0.004).

30 This rate was higher than those seen with T. vaginalis (9.0%; P = 0.005), C. trachomatis (6.2%), and

31 Gardnerella vaginalis, a facultative anaerobe, was cleared more slow

32 Trichomonas vaginalis, a flagellated protozoan, is the agent respons

33 In Trichomonas vaginalis, a Myb1 protein was previously demonstrated to

34 Among them, Trichomonas vaginalis, a parasite adapted to the human genitourinary

35 logistic regression model that identifiedG. vaginalis,A. vaginae, andMegasphaeraphylotypes 1 and 2 a

36 ome evidence of association with Trichomonas vaginalis (adjusted OR, 1.56; 95% CI, 1.00-2.44).

37 The T. vaginalis alpha-actinin amino acid sequence and the sequ

38 Comparison of the T. vaginalis alpha-actinin epitopes with proteins in data b

39 divergent unicellular eukaryote Trichomonas vaginalis, although genome analyses reveal that only app

40 mens submitted for live clinical Trichomonas vaginalis analyte-specific reagent (ASR) screening from

41 ver, first-void urine detection rates for T. vaginalis and C. trachomatis within this age demographic

42 d 0.24% for C. trachomatis/N. gonorrhoeae/T. vaginalis and highest in women <30 years old.

43 Additional Trichomonas vaginalis and Mycoplasma genitalium screening found 17.4

44 on the influence of biofilm formation by G. vaginalis and other anaerobes, from the time of their in

45 cillus women, negatively correlating with G. vaginalis and other anaerobic bacteria, which depleted t

46 Ts and specific bacterial phyla (Gardnerella vaginalis and Prevotella bivia) were strongly associated

47 ired STIs included chlamydia, gonorrhoea, T. vaginalis and syphilis with rapid plasma reagin >/=1:8.

48 Trichomonas vaginalis and viral pathogens (herpes simplex virus type

49 al organs (testicles, spermatic cord, tunica vaginalis) and is characterized by pain, swelling and hy

50 chomatis, Neisseria gonorrhoeae, Trichomonas vaginalis) and the E6/E7 mRNA of human papillomavirus (H

51 homatis/N. gonorrhoeae and N. gonorrhoeae/T. vaginalis, and 0.24% for C. trachomatis/N. gonorrhoeae/T

52 gonorrhoeae, 26 (5.2%) were positive for T. vaginalis, and 47 (9.5%) were positive for M. genitalium

53 thia species, Atopobium species, Gardnerella vaginalis, and a Megasphaera-like bacterium, suggesting

54 , Parvimonas micra, Megasphaera, Gardnerella vaginalis, and Atopobium vaginae and decreased frequenci

55 Associated Bacterium 2 (BVAB-2), Gardnerella vaginalis, and Megasphaera-1--and a single organism (Lac

56 cteria: Lactobacillus crispatus, Gardnerella vaginalis, and Neisseria gonorrhoeae All vaginal microbi

57 inal pathogens Candida albicans, Gardnerella vaginalis, and Neisseria gonorrhoeae, as well as to toxi

58 as detected between the leaves of the tunica vaginalis, and rupture from the lower pole was diagnosed

59 .01), Lactobacillus fermentum, Lactobacillus vaginalis, and S. mutans with Streptococcus sobrinus (al

60 nic protozoa Giardia lamblia and Trichomonas vaginalis, and the bacterial pathogens Helicobacter pylo

61 gilis, Pentatrichomonas hominis, Trichomonas vaginalis, and Trichomonas tenax.

62 mpling devices for Candida spp., Gardnerella vaginalis, and Trichomonas vaginalis.

63 els were lower in females with a positive T. vaginalis antigen test result, a vaginal pH >4.5, vagina

64 G. vaginalis appears to include four nonrecombining groups/

65 High vaginal loads of A. vaginae and G. vaginalis are associated with late miscarriage and prema

66 lamblia, Leishmania species, and Trichomonas vaginalis are persistently infected with dsRNA viruses,

67 Biofilms of G. vaginalis are present in human infections and are implic

68 Sera from patients infected with T. vaginalis are reactive to TvMIF, especially in males.

69 T. vaginalis ASR is an increasingly utilized assay that yie

70 gonorrhoeae infection overall, a positive T. vaginalis ASR result was a better predictor of concomita

71 relative light unit (RLU) data yielded by T. vaginalis ASR.

72 alis prevalence using the Aptima Trichomonas vaginalis assay (ATV; Gen-Probe) and the prevalence of C

73 d the performance of the automated Aptima T. vaginalis assay for detecting T. vaginalis in 1,025 asym

74 es the clinical performance of the Aptima T. vaginalis assay for screening asymptomatic and symptomat

75 Aptima T. vaginalis assay performance was determined for each spec

76 ercial NAA test (GenProbe Aptima Trichomonas vaginalis assay; ATV) for T. vaginalis were compared wit

77 bacterial communities containing Gardnerella vaginalis associated with vaginal drying, whereas DMPA s

78 lli and higher concentrations of Gardnerella vaginalis, Atopobium vaginae, and Prevotella bivia, at t

79 Lactobacillus iners, Gardnerella vaginalis, Atopobium vaginae, Megasphaera I, and Megasph

80 d with vaginal health or disease:Gardnerella vaginalis,Atopobium vaginae, BV-associated bacteria 2 (B

81 e tested by the TVQ assay, and the Aptima T. vaginalis (ATV) assay was performed using clinician-coll

82 bridization assay to the Gen-Probe Aptima T. vaginalis (ATV) transcription-mediated amplification (TM

83 hem to understand the phenotypic shift of G. vaginalis biofilm formation to BV establishment.

84 Here we demonstrate that G. vaginalis biofilms contain extracellular DNA, which is e

85 s and approaches available to interrogate T. vaginalis biology, with an emphasis on recent advances a

86 ues following intravaginal infection with T. vaginalis but were not seen in uninfected mice.

87 n tests (NAATs) for detection of Trichomonas vaginalis by vaginal swabs; NAATs for detection of Neiss

88 Overall, T. vaginalis, C. trachomatis, and N. gonorrhoeae prevalence

89 ported in females, TMA-based detection of T. vaginalis can be a routine constituent within a comprehe

90 The human-infective parasite Trichomonas vaginalis causes the most prevalent nonviral sexually tr

91 mplified the beta-fructofuranosidase from T. vaginalis cDNA and cloned it into an Escherichia coli ex

92 etect beta-fructofuranosidase activity in T. vaginalis cell lysates.

93 tic Trichomonasvirus, highly prevalent in T. vaginalis clinical isolates, is sensed by the human epit

94 Aptima T. vaginalis clinical sensitivity and specificity were, res

95 In females with detectable T. vaginalis, codetection of Chlamydia trachomatis and Neis

96 is, we demonstrate >10-fold inhibition of G. vaginalis colonization by DNase.

97 Trichomonas vaginalis colonizes the urogenital tract of humans and c

98 a single, agar-cloned clinical isolate of T. vaginalis, confirming the natural capacity for concurren

99 The extracellular parasite Trichomonas vaginalis contains a surface glycoconjugate that appears

100 ntracellular redox buffer by showing that T. vaginalis contains high levels of cysteine ( approximate

101 s with Chlamydia trachomatis and Trichomonas vaginalis decreases the prophylactic efficacy of oral em

102 no difference between urethral and urine T. vaginalis detection (P = 0.53).

103 in improving the sensitivity of Trichomonas vaginalis detection in young women over that of a wet mo

104 traurogenital sources into assessment for T. vaginalis detection may identify additional symptomatic

105 Combined-gender T. vaginalis detection rate (9.1%) was significantly greate

106 , 858 pharyngeal specimens yielded a 2.9% T. vaginalis detection rate compared with 2.1% for N. gonor

107 T. vaginalis detection rate in males was 6.6%, with no diff

108 The aggregate T. vaginalis detection rate trended higher than that of the

109 o significant difference was noted in the T. vaginalis detection rates (8.9 and 8.6%, P = 0.85).

110 The M. genitalium and T. vaginalis detection rates among 755 patients at urban em

111 Increased T. vaginalis detection was derived from female urine specim

112 Given the significant rate of T. vaginalis detection, with age distribution analogous to

113 The stability of T. vaginalis DNA in 40 urine samples was assessed by storag

114 identify a simple method for stabilizing T. vaginalis DNA in urine samples that could be easily appl

115 T. vaginalis DNA was stable in specimens stored without usi

116 Overall, there was better stability of T. vaginalis DNA when specimens were stored at 4 degrees C

117 hain reaction (PCR) analysis for Trichomonas vaginalis DNA.

118 It has been reported that T. vaginalis does not grow on sucrose.

119 Eight DRP homologues [T. vaginalis DRPs (TvDRPs)], which can be grouped into 3 su

120 G. vaginalis engaged in sialoglycan foraging in vitro, in t

121 , and that a subspecies clade of Gardnerella vaginalis explained the genus association with PTB.

122 n substrates supports a model in which 1) G. vaginalis extracellular sialidase hydrolyzes mucosal sia

123 While positive T. vaginalis findings via direct saline preparation did not

124 sis of GAPDH by antisense transfection of T. vaginalis gave lower levels of organisms bound to FN and

125 ning 5' untranslated regions of expressed T. vaginalis genes was searched for overrepresented DNA mot

126 Nevertheless, the T. vaginalis genome contains some 11 putative sucrose trans

127 crobial activity with complete inhibition G. vaginalis growth within 48 h.

128 Our data suggests that Gardnerella vaginalis had the highest virulence potential, as define

129 utility of TMA for detection of Trichomonas vaginalis has recently been described.

130 T. vaginalis has the coding capacity to produce an active b

131 ania spp., Trypanosoma cruzi and Trichomonas vaginalis have genes encoding homologues of Piezo channe

132 eic acid amplification tests for Trichomonas vaginalis have improved sensitivity for detecting infect

133 y as women with fewer partners to acquire T. vaginalis (hazard ratio, 4.3; 95% CI, 2.0-9.4).

134 cate a role for a TvDRP in the fission of T. vaginalis hydrogenosomes, similar to that described for

135 ect N. gonorrhoeae and C. trachomatis (or T. vaginalis if utilized), there is no US Food and Drug Adm

136 d Aptima T. vaginalis assay for detecting T. vaginalis in 1,025 asymptomatic and symptomatic women.

137 atis, Neisseria gonorrhoeae, and Trichomonas vaginalis in liquid-based cytology specimens were 1.5, 2

138 detect Mycoplasma genitalium and Trichomonas vaginalis in men and women reporting a history of recept

139 Detection of G. vaginalis in oral cavity or anal samples and Leptotrichi

140 Changes in MST activity of T. vaginalis in response to variation in the supply of exog

141 Currently, the role of G. vaginalis in the etiology of BV remains a matter of cont

142 and specific PCR assays for detection of T. vaginalis in urine, a noninvasive specimen, and developm

143 s warrants a more thorough review of male T. vaginalis incidence.

144 d divergence of the vaginal microbiota in T. vaginalis-infected and T. vaginalis-uninfected patients

145 s (24.7 years) was lower than that of the T. vaginalis-infected females (mean, 30.1 years; P < 0.0001

146 The average age of a T. vaginalis-infected male (39.9 years) was significantly g

147 pothesized that the vaginal microbiota in T. vaginalis-infected women differs from that in T. vaginal

148 Vaginal samples from 30 T. vaginalis-infected women were matched by Nugent score to

149 ster analysis revealed 2 unique groups of T. vaginalis-infected women.

150 g and treating females with low levels of T. vaginalis infection (before they become wet mount positi

151 ction, as well as the association between T. vaginalis infection and increased transmission of and su

152 incidence and increased the clearance of T. vaginalis infection and induced both systemic and local

153 s have been correlated with both Trichomonas vaginalis infection and poor reproductive health outcome

154 The prevalence of T. vaginalis infection before HIV infection was 11.3% in ca

155 The presence of CD4(+) T cells following T. vaginalis infection can potentially increase susceptibil

156 Trichomonas vaginalis infection in males has been largely uncharacte

157 C. trachomatis and T. vaginalis infection increase the susceptibility to SHIV,

158 The prevalence of Trichomonas vaginalis infection is highest in women with intermediat

159 T. vaginalis infection is strongly associated with an incre

160 cantly higher than the N. gonorrhoeae and T. vaginalis infection rates.

161 the potential for a human vaccine against T. vaginalis infection that could also influence the incide

162 o the diagnosis and treatment of Trichomonas vaginalis infection, as well as the association between

163 rding conditions associated with Trichomonas vaginalis infection, including human immunodeficiency vi

164 ng 30 to 40 years of age, recent Trichomonas vaginalis infection, primary or recurrent genital herpes

165 leukocytosis, and recurrent (vs initial) T. vaginalis infection, with the lowest levels observed in

166 and Neisseria gonorrhoeae with concurrent T. vaginalis infection.

167 ations were significantly associated with T. vaginalis infection.

168 ng asymptomatic and symptomatic women for T. vaginalis infection.

169 oeae, Chlamydia trachomatis, and Trichomonas vaginalis infection.

170 Trichomonas vaginalis infections are usually asymptomatic or can res

171 oeae, Mycoplasma genitalium, and Trichomonas vaginalis infections as well as the characteristics of b

172 ogether, these data indicate that chronic T. vaginalis infections may result in TvMIF-driven inflamma

173 the pathogenesis and disease outcomes of T. vaginalis infections of the human genital mucosa.

174 culture or wet mount for the diagnosis of T. vaginalis infections.

175 Gardnerella vaginalis is a bacterial species associated with bacteri

176 Trichomonas vaginalis is a common sexually transmitted infection (ST

177 Trichomonas vaginalis is a highly divergent, unicellular eukaryote o

178 Trichomonas vaginalis is a parasite of the urogenital tract in men a

179 Gardnerella vaginalis is a predominant bacterial species, but BV is

180 Trichomonas vaginalis is a protozoan parasite of humans that is able

181 Trichomonas vaginalis is an extracellular protozoan parasite that bi

182 Trichomonas vaginalis is an important pathogen in both men and women

183 Trichomonas vaginalis is an underestimated sexually transmitted infe

184 Gardnerella vaginalis is associated with a spectrum of clinical cond

185 Until a NAAT for T. vaginalis is commercially available, a stepwise approach

186 However, T. vaginalis is disproportionality under studied, especiall

187 T. vaginalis is the most common sexually transmitted infect

188 Gardnerella vaginalis is the most common species found in bacterial

189 Trichomonas vaginalis is the most prevalent nonviral sexually transm

190 Trichomonas vaginalis is the most prevalent nonviral sexually transm

191 G. vaginalis is the pathogen responsible for the initiation

192 formed on the vaginal epithelium and that G. vaginalis is typically the predominant species.

193 better understand the differences between G. vaginalis isolated from women with a positive (BV) versu

194 virulence potential of 7 BV and 7 non-BV G. vaginalis isolates and assessed the virulence factors re

195 Moreover, 2 of these other T. vaginalis isolates are concurrently infected by strains

196 erent dsRNA molecules obtained from a few T. vaginalis isolates has suggested that more than one viru

197 Seventeen G. vaginalis isolates were subjected to a battery of compar

198 on quantified Atopobium vaginae, Gardnerella vaginalis, lactobacilli, Mycoplasma hominis, and the hum

199 eting 16S ribosomal RNA genes of Gardnerella vaginalis, Lactobacillus crispatus, BVAB1, BVAB2, BVAB3,

200 ur data reveal a complex structure, named T. vaginalis lipoglycan (TvLG), that differs markedly from

201 The SLPI level was reduced by >50% in a T. vaginalis load-dependent manner.

202 levels observed in those with the highest T. vaginalis loads.

203 und that T. vaginalis secretes a protein, T. vaginalis macrophage migration inhibitory factor (TvMIF)

204 G. vaginalis makes a protein toxin that generates host immu

205 T. vaginalis may alter the vaginal microbiota in a manner t

206 The genetic diversity of G. vaginalis may result in virulent and avirulent strains.

207 We have found that T. vaginalis mRNAs are protected by a 5' cap structure, how

208 d with Chlamydia trachomatis and Trichomonas vaginalis (n = 9) or medium (controls; n = 7) were repea

209 e of extragenital infection with Trichomonas vaginalis of the conjunctiva of a 32-year-old man.

210 obic BV-associated species, and levels of G. vaginalis often rebounded during treatment.

211 who used drugs were screened for Trichomonas vaginalis on > or =2 occasions between March 2003 and Au

212 ed rapid point-of-care tests for Trichomonas vaginalis on self-collected vaginal swabs.

213 s of the score (ie, detection of Gardnerella vaginalis or Bacteroides spp and non-detection of Lactob

214 ntly different between women with detected G vaginalis or Bacteroides spp morphotypes and those witho

215 hybridomas that inhibited the binding of T. vaginalis organisms to immobilized FN was identified.

216 gents) and 26.1% were solely positive for T. vaginalis (P < 0.0002 versus C. trachomatis).

217 Sneathia species (P=0.0002), and Gardnerella vaginalis (P<0.0001).

218 Aptima T. vaginalis performance levels were similar in asymptomati

219 All T. vaginalis pharyngeal detections were confirmed by TMA-ba

220 gens, as well as protozoa, e.g., Trichomonas vaginalis, Plasmodium berghei, and sporozoites and blood

221 and phylogenetic analyses determined that T. vaginalis population structure is strongly influenced by

222 mong the 68 isolates, revealing a diverse T. vaginalis population.

223 (95% confidence interval, 1.25-6.00) for T. vaginalis-positive cases.

224 A total of 85.7% of males with T. vaginalis-positive pharyngeal collections indicated stri

225 A total of 38.1% of T. vaginalis-positive pharyngeal specimens were derived fro

226 four primary tests was considered a true T. vaginalis-positive result.

227 llus (59.2%) and the other where Gardnerella vaginalis predominated with other anaerobic bacteria (40

228 Gardnerella vaginalis predominates in bacterial vaginosis.

229 e evaluated with more-sensitive tests for T. vaginalis, preferably NAATs, if microscopy is negative.

230 T. vaginalis prevalence differed by race/ethnicity, with th

231 High T. vaginalis prevalence in all age groups suggests that wom

232 alth care system was performed to address T. vaginalis prevalence in males.

233 Higher T. vaginalis prevalence in women of >40 years is probably a

234 T. vaginalis prevalence ranged from 5.4% in family planning

235 Our aim was to determine Trichomonas vaginalis prevalence using the Aptima Trichomonas vagina

236 The highest T. vaginalis prevalence was in women >/= 40 years old (>11%

237 ond ATV TMA assay, utilizing an alternate T. vaginalis primer and probe set, was performed on all spe

238 ed in vitro by the catalytic subunit of a T. vaginalis protein kinase A, TvPKAc.

239 we describe the performance of the new BD T. vaginalis Qx (TVQ) amplified DNA assay, which can be per

240 T. vaginalis research entered the age of genomics with the

241 atabases for Giardia lamblia and Trichomonas vaginalis, respectively, and represent the latest additi

242 om Streptococcus intermedius and Gardnerella vaginalis, respectively.

243 oned from Pseudomonas putida and Trichomonas vaginalis, respectively.

244 care professionals can consider TMA-based T. vaginalis screening for a wide age range of patients; in

245 A control strategy that includes T. vaginalis screening in nonclinical settings and rapid po

246 tandard for clinical culture for Trichomonas vaginalis screening.

247 We have found that T. vaginalis secretes a protein, T. vaginalis macrophage mi

248 atis, Neisseria gonorrhoeae, and Trichomonas vaginalis Sequencing was used to assess macrolide antibi

249 contrary to that typical for eukaryotes, T. vaginalis spliceosomal snRNAs lack a cap and may contain

250 study, we examined the propensities of 26 T. vaginalis strains to bind to and lyse prostate (BPH-1) a

251 asure, the degree of difference among the G. vaginalis strains was the highest observed among 23 path

252 of pathogenic properties among different T. vaginalis strains, all strains show strict contact-depen

253 The InPouch Trichomonas vaginalis test is the gold standard for clinical culture

254 ed-patient status was defined as positive T. vaginalis test results by at least 2 assays.

255 e compared with the Affirm VPIII Trichomonas vaginalis test.

256 we biochemically characterize the single T. vaginalis Tgs (TvTgs) encoded in its genome and demonstr

257 Gardnerella vaginalis, the bacterial species most frequently isolate

258 Trichomoniasis vaginalis, the most prevalent nonviral sexually transmit

259 s for C. trachomatis, N. gonorrhoeae, and T. vaginalis TMA screening.

260 ermore, we also determined the ability of G. vaginalis to displace lactobacilli previously adhered to

261 syphilis, chlamydia, gonorrhoea, Trichomonas vaginalis (together defined as 'any STI') and HIV-1.

262 s reported increased accuracy of Trichomonas vaginalis transcription-mediated amplification (TMA)-bas

263 t and persistent infections with Trichomonas vaginalis (TV) are common.

264 Mycoplasma genitalium (MG), and Trichomonas vaginalis (TV) are sexually transmitted infections (STIs

265 Trichomonas vaginalis (TV) is the most common nonviral sexually tran

266 urealyticum biovar 2 (UU-2), and Trichomonas vaginalis (TV) using nucleic acid amplification tests.

267 lvovaginal candidiasis (VVC), or Trichomonas vaginalis (TV), were randomly assigned to receive vagina

268 l microbiota in T. vaginalis-infected and T. vaginalis-uninfected patients among women with normal an

269 nalis-infected women differs from that in T. vaginalis-uninfected women.

270 matched by Nugent score to those from 30 T. vaginalis-uninfected women.

271 that the BV-associated bacterium Gardnerella vaginalis uses sialidase to break down and deplete siali

272 Taken together, these studies show that G. vaginalis utilizes sialidase to support the degradation,

273 aluminum hydroxide-adjuvanted whole-cell T. vaginalis vaccine for efficacy in a BALB/c mouse model o

274 A whole-cell T. vaginalis vaccine was administered subcutaneously to BAL

275 gnificant proportion of healthy women and G. vaginalis vaginal colonization does not always lead to B

276 rus 2 infection, genital ulcers, Trichomonas vaginalis, vaginitis or cervicitis, and male circumcisio

277 atis, Neisseria gonorrhoeae, and Trichomonas vaginalis via commercial transcription-mediated amplific

278 to be more thermoresistant than Trichomonas vaginalis virus 1, but no specific protein machinery to

279 uding Leishmania RNA viruses and Trichomonas vaginalis viruses.

280 T. vaginalis was more prevalent than C. trachomatis or N. g

281 T. vaginalis was most prevalent in women who were 36 to 45

282 T. vaginalis was the predominant sexually transmitted agent

283 ing primers against pfoB gene of Trichomonas vaginalis, was developed and evaluated using dry ectocer

284 new murine vaginal colonization model for G. vaginalis, we demonstrate >10-fold inhibition of G. vagi

285 for the regulation of cysteine levels in T. vaginalis, we have characterized enzymes of the mercapto

286 lium, C. trachomatis, N. gonorrhoeae, and T. vaginalis were 100, 70, 67, and 20%, respectively.

287 ue to N. gonorrhoeae, C. trachomatis, and T. vaginalis were 3.48, 4.55, and 1.32 cases per 100 person

288 antly, we demonstrated that BV associated G. vaginalis were able to displace pre-coated vaginal prote

289 loads of either or both of A. vaginae and G. vaginalis were associated with preterm birth (hazard rat

290 ima Trichomonas vaginalis assay; ATV) for T. vaginalis were compared with the Affirm VPIII Trichomona

291 oeae, Chlamydia trachomatis, and Trichomonas vaginalis were performed.

292 y-eight historical and recent isolates of T. vaginalis were sampled from the American Type Culture Co

293 838 women, 116 of whom were infected with T. vaginalis, were analyzed.

294 Trichomonas vaginalis, which causes the most common nonviral sexuall

295 ed by the sexual transmission of Gardnerella vaginalis, which has the appropriate virulence factors t

296 against the primary BV pathogen Gardnerella vaginalis with a minimum inhibitory concentration (MIC)

297 GAPDH is a surface-associated protein of T. vaginalis with alternative functions.

298 We have shown an association of T. vaginalis with basement membrane extracellular matrix co

299 l swab and first-void urine screening for T. vaginalis within a regional health care system was perfo

300 nd cervical specimen-derived detection of T. vaginalis within African American majority geographical